Reports Q2 revenue $116.2M, consensus $110.36M. “Our strong Q2 performance reflects outstanding execution of our strategies of advancing ...

Accuray (NASDAQ:ARAY – Get Free Report) was upgraded by equities researchers at StockNews.com from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Monday.

Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the second quarter ended December 31, 2024. Key ...

president and CEO of Accuray. "Our continued innovation in product and service offerings are helping close the gaps to cancer care and expand on the curative power of radiation therapy to improve ...

Welcome to Accuray’s conference call to review financial ... and improving patient access to radiotherapy in developing markets where we believe we can grow faster than the market and achieve ...

Accuray Incorporated (NASDAQ:ARAY), a company specializing in surgical and medical instruments with a market capitalization of $250 million, announced the appointment of Leonel Peralta as its new ...

Accuray beat estimated earnings by 150.0%, reporting an EPS of $0.02 versus an estimate of $-0.04. Revenue was up $8.94 million from the same period last year. The company beat on EPS by $0.01 in ...

Welcome to Accuray's conference call to review financial results for the second quarter ... These include advancing cancer care through innovation, expanding our service solutions business, and ...

Accuray Incorporated beats earnings expectations ... and improving patient access to radiotherapy in developing markets where we believe we can grow faster than the market and achieve number ...

The anticorruption campaign in China was noted as a potential risk, though Accuray’s unique JV structure and product differentiation provide mitigation. Tariff uncertainties under the new U.S ...